Evidence map›Paper›PMID 39919199›Full record

ArticleScience immunology2025

Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma.

Raphael Lutz, Alexandra M Poos, Llorenç Solé-Boldo, Lukas John, Johanna Wagner, Nina Prokoph, Marc A Baertsch, Dominik Vonficht, Subarna Palit, Alexander Brobeil and 25 more

Abstract read
In one paragraph

Article in Science immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Raphael LutzHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0009-0004-6214-308X
Alexandra M PoosHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0009-0009-4325-3933
Llorenç Solé-BoldoBerlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-6974-9066
Lukas JohnHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0001-8178-6890
Johanna WagnerDivision of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-5087-3657
Nina ProkophHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-6429-9895
Marc A BaertschHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-4000-6904
Dominik VonfichtHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.
Subarna PalitBerlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.
Alexander BrobeilDepartment of Pathology, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Gunhild MechtersheimerDepartment of Pathology, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-9442-3930
Nina HildenbrandDepartment of Orthopaedics, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-3988-2018
Stefan HemmerDepartment of Orthopaedics, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0009-0000-8696-2099
Simon SteigerDivision of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany.ORCID 0000-0002-4845-5042
Sabrina HornBerlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.
Wojciech PepkeDepartment of Orthopaedics, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0001-9690-4511
David M SpranzDepartment of Orthopaedics, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Christoph RehnitzDepartment of Radiology, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Pooja SantSingle Cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-9301-3211
Jan-Philipp MallmSingle Cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-7059-4030
Mirco J FriedrichHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-6401-3623
Philipp ReichertHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Stefanie HuhnHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Andreas TrumppHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.ORCID 0000-0002-6212-3466
Karsten RippeDivision of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany.ORCID 0000-0001-9951-9395
Laleh HaghverdiBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Stefan FröhlingDivision of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-7907-4595
Carsten Müller-TidowNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-7166-5232
Daniel HübschmannHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.ORCID 0000-0002-6041-7049
Hartmut GoldschmidtHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0003-0961-0035
Gerald WillimskyBerlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-9693-948X
Sandra SauerHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Marc S RaabHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Simon HaasBerlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0001-9227-2051
Niels WeinholdHeidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-5464-3234

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The bone marrow microenvironment plays a crucial role in the development of multiple myeloma. As the disease progresses, malignant myeloma cells can evolve to survive outside the bone marrow. However, the processes underlying bone marrow independence and their consequences for immune control remain poorly understood. Here, we conducted single-cell and spatial multiomics analyses of bone marrow-confined intramedullary disease and paired breakout lesions that disrupt the cortical bone. These analyses revealed a distinct cellular microenvironment and architectural features of breakout lesions, characterized by extensive areas of malignant plasma cells interspersed with lesion-specific solitary natural killer and macrophage populations, as well as focal accumulations of immune cell agglomerates. Within these agglomerates, spatially confined T cell clones expanded alongside various immune cells, coinciding with the local genomic evolution of tumor cells. These analyses identify breakout lesions as a hotspot for tumor-immune cell interactions and diversification, representing a key event in myeloma pathogenesis.

Indexed as

Bone MarrowMultiple MyelomaTumor MicroenvironmentAnimalsHumansKiller Cells, NaturalMacrophagesPlasma CellsSingle-Cell Analysis

Identifiers

PMID39919199
PMCPMC7619224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.